GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Synthetic organic
Comment: The IUPAC descriptor for this compound was obtained from the FDA's list of Orphan Drug Designations and Approvals [1]. It maps to a chemical structure claimed in patent WO2020160054A1, for activity as a Toll-like receptor 7 (TLR7) and/or TLR8 agonist [2]. We suspect that this is CAN1012 (CanWell Pharma), a selective TLR7 agonist, but the structure of CAN1012 has not been formally disclosed.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| This small molecule was granted FDA orphan drug designation in February 2026, to treat soft tissue sarcoma [1]. CAN1012 is under evaluation in clinical studies, to determine safety and anti-tumour efficacy. |